Irvine, CA — December 19, 2025: Cassderma Rx, a California-based biotech company, has received preliminary FDA clearance to advance its patented wound-healing therapy, CAS101, directly into Phase 2 clinical trials—bypassing traditional Phase 1 requirements. This fast-track decision reflects the therapy’s strong preclinical safety profile and addresses a major unmet need in chronic wound care, which affects over 8 million Americans and costs more than $30 billion annually. Led by regulatory expert Dr. Daniel Rastein, Cassderma is finalizing GLP toxicology and GMP ingredient studies through partnerships with Frontage Laboratories and SGS Pharma. Supported by PFD Capital Partners, the company is positioned for near-term IND filing and significant value creation.